NM_021098.3:c.5947T>C
Variant names:
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_021098.3(CACNA1H):c.5947T>C(p.Leu1983Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.608 in 1,549,694 control chromosomes in the GnomAD database, including 290,331 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.64 ( 31617 hom., cov: 32)
Exomes 𝑓: 0.60 ( 258714 hom. )
Consequence
CACNA1H
NM_021098.3 synonymous
NM_021098.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -2.70
Publications
23 publications found
Genes affected
CACNA1H (HGNC:1395): (calcium voltage-gated channel subunit alpha1 H) This gene encodes a T-type member of the alpha-1 subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. The alpha-1 subunit has 24 transmembrane segments and forms the pore through which ions pass into the cell. There are multiple isoforms of each of the proteins in the complex, either encoded by different genes or the result of alternative splicing of transcripts. Alternate transcriptional splice variants, encoding different isoforms, have been characterized for the gene described here. Studies suggest certain mutations in this gene lead to childhood absence epilepsy (CAE). [provided by RefSeq, Jul 2008]
CACNA1H Gene-Disease associations (from GenCC):
- hyperaldosteronism, familial, type IVInheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
- childhood absence epilepsyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, childhood absence, susceptibility to, 6Inheritance: AD Classification: LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 16-1219029-T-C is Benign according to our data. Variant chr16-1219029-T-C is described in ClinVar as Benign. ClinVar VariationId is 518260.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-2.7 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.855 is higher than 0.05.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CACNA1H | ENST00000348261.11 | c.5947T>C | p.Leu1983Leu | synonymous_variant | Exon 34 of 35 | 1 | NM_021098.3 | ENSP00000334198.7 | ||
| CACNA1H | ENST00000569107.6 | c.5962T>C | p.Leu1988Leu | synonymous_variant | Exon 33 of 34 | 1 | ENSP00000454990.2 | |||
| CACNA1H | ENST00000711493.1 | c.5932T>C | p.Leu1978Leu | synonymous_variant | Exon 33 of 34 | ENSP00000518778.1 | ||||
| CACNA1H | ENST00000565831.7 | c.5929T>C | p.Leu1977Leu | synonymous_variant | Exon 33 of 34 | 1 | ENSP00000455840.1 | |||
| CACNA1H | ENST00000711450.1 | c.5929T>C | p.Leu1977Leu | synonymous_variant | Exon 34 of 35 | ENSP00000518762.1 | ||||
| CACNA1H | ENST00000564231.6 | c.5914T>C | p.Leu1972Leu | synonymous_variant | Exon 34 of 35 | 1 | ENSP00000457555.2 | |||
| CACNA1H | ENST00000638323.1 | c.5908T>C | p.Leu1970Leu | synonymous_variant | Exon 34 of 35 | 5 | ENSP00000492267.1 | |||
| CACNA1H | ENST00000562079.6 | c.5896T>C | p.Leu1966Leu | synonymous_variant | Exon 33 of 34 | 1 | ENSP00000454581.2 | |||
| CACNA1H | ENST00000711438.1 | c.5890T>C | p.Leu1964Leu | synonymous_variant | Exon 33 of 34 | ENSP00000518754.1 | ||||
| CACNA1H | ENST00000711482.1 | c.5947T>C | p.Leu1983Leu | synonymous_variant | Exon 34 of 36 | ENSP00000518771.1 | ||||
| CACNA1H | ENST00000711485.1 | c.5896T>C | p.Leu1966Leu | synonymous_variant | Exon 33 of 35 | ENSP00000518774.1 | ||||
| CACNA1H | ENST00000711483.1 | c.5947T>C | p.Leu1983Leu | synonymous_variant | Exon 34 of 35 | ENSP00000518772.1 | ||||
| CACNA1H | ENST00000621827.2 | n.5947T>C | non_coding_transcript_exon_variant | Exon 34 of 37 | 6 | ENSP00000518766.1 | ||||
| CACNA1H | ENST00000637236.3 | n.*1866T>C | non_coding_transcript_exon_variant | Exon 33 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.*995T>C | non_coding_transcript_exon_variant | Exon 34 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*3765T>C | non_coding_transcript_exon_variant | Exon 34 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*5391T>C | non_coding_transcript_exon_variant | Exon 32 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.*888T>C | non_coding_transcript_exon_variant | Exon 35 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.*806T>C | non_coding_transcript_exon_variant | Exon 34 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.*1526T>C | non_coding_transcript_exon_variant | Exon 35 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.*614T>C | non_coding_transcript_exon_variant | Exon 35 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.*581T>C | non_coding_transcript_exon_variant | Exon 35 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711484.1 | n.5896T>C | non_coding_transcript_exon_variant | Exon 33 of 35 | ENSP00000518773.1 | |||||
| CACNA1H | ENST00000711486.1 | n.5947T>C | non_coding_transcript_exon_variant | Exon 34 of 37 | ENSP00000518775.1 | |||||
| CACNA1H | ENST00000711487.1 | n.5914T>C | non_coding_transcript_exon_variant | Exon 34 of 36 | ENSP00000518776.1 | |||||
| CACNA1H | ENST00000711488.1 | n.*1063T>C | non_coding_transcript_exon_variant | Exon 34 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000637236.3 | n.*1866T>C | 3_prime_UTR_variant | Exon 33 of 34 | 5 | ENSP00000492650.2 | ||||
| CACNA1H | ENST00000639478.1 | n.*995T>C | 3_prime_UTR_variant | Exon 34 of 35 | 5 | ENSP00000491945.1 | ||||
| CACNA1H | ENST00000640028.1 | n.*3765T>C | 3_prime_UTR_variant | Exon 34 of 35 | 5 | ENSP00000491488.1 | ||||
| CACNA1H | ENST00000711442.1 | n.*5391T>C | 3_prime_UTR_variant | Exon 32 of 34 | ENSP00000518758.1 | |||||
| CACNA1H | ENST00000711448.1 | n.*888T>C | 3_prime_UTR_variant | Exon 35 of 36 | ENSP00000518760.1 | |||||
| CACNA1H | ENST00000711449.1 | n.*806T>C | 3_prime_UTR_variant | Exon 34 of 35 | ENSP00000518761.1 | |||||
| CACNA1H | ENST00000711451.1 | n.*1526T>C | 3_prime_UTR_variant | Exon 35 of 36 | ENSP00000518763.1 | |||||
| CACNA1H | ENST00000711452.1 | n.*614T>C | 3_prime_UTR_variant | Exon 35 of 36 | ENSP00000518764.1 | |||||
| CACNA1H | ENST00000711453.1 | n.*581T>C | 3_prime_UTR_variant | Exon 35 of 36 | ENSP00000518765.1 | |||||
| CACNA1H | ENST00000711488.1 | n.*1063T>C | 3_prime_UTR_variant | Exon 34 of 35 | ENSP00000518777.1 | |||||
| CACNA1H | ENST00000711455.1 | c.5888-19T>C | intron_variant | Intron 33 of 35 | ENSP00000518768.1 | |||||
| CACNA1H | ENST00000711456.1 | c.5887+378T>C | intron_variant | Intron 33 of 33 | ENSP00000518769.1 |
Frequencies
GnomAD3 genomes AF: 0.640 AC: 97285AN: 151948Hom.: 31593 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
97285
AN:
151948
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.651 AC: 100039AN: 153568 AF XY: 0.640 show subpopulations
GnomAD2 exomes
AF:
AC:
100039
AN:
153568
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.605 AC: 845136AN: 1397628Hom.: 258714 Cov.: 48 AF XY: 0.603 AC XY: 415485AN XY: 689396 show subpopulations
GnomAD4 exome
AF:
AC:
845136
AN:
1397628
Hom.:
Cov.:
48
AF XY:
AC XY:
415485
AN XY:
689396
show subpopulations
African (AFR)
AF:
AC:
21133
AN:
31590
American (AMR)
AF:
AC:
25975
AN:
35682
Ashkenazi Jewish (ASJ)
AF:
AC:
17477
AN:
25156
East Asian (EAS)
AF:
AC:
32203
AN:
35732
South Asian (SAS)
AF:
AC:
44534
AN:
79220
European-Finnish (FIN)
AF:
AC:
33087
AN:
47960
Middle Eastern (MID)
AF:
AC:
3987
AN:
5684
European-Non Finnish (NFE)
AF:
AC:
630478
AN:
1078642
Other (OTH)
AF:
AC:
36262
AN:
57962
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
17161
34321
51482
68642
85803
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
17676
35352
53028
70704
88380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.640 AC: 97352AN: 152066Hom.: 31617 Cov.: 32 AF XY: 0.648 AC XY: 48152AN XY: 74338 show subpopulations
GnomAD4 genome
AF:
AC:
97352
AN:
152066
Hom.:
Cov.:
32
AF XY:
AC XY:
48152
AN XY:
74338
show subpopulations
African (AFR)
AF:
AC:
27437
AN:
41490
American (AMR)
AF:
AC:
10701
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
AC:
2473
AN:
3472
East Asian (EAS)
AF:
AC:
4517
AN:
5152
South Asian (SAS)
AF:
AC:
2721
AN:
4822
European-Finnish (FIN)
AF:
AC:
7525
AN:
10594
Middle Eastern (MID)
AF:
AC:
206
AN:
294
European-Non Finnish (NFE)
AF:
AC:
39875
AN:
67930
Other (OTH)
AF:
AC:
1375
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
1785
3570
5355
7140
8925
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
792
1584
2376
3168
3960
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2506
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
Nov 27, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Epilepsy, childhood absence, susceptibility to, 6 Benign:2
-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
Jul 28, 2017
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Idiopathic generalized epilepsy;C4310756:Hyperaldosteronism, familial, type IV Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.